Skip to Main Content

Author Details

Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
2010
398
54
PMIDPaper TitleJournal TitlePublished Year
36526683Radiotherapy in patients with node-positive prostate cancer after radical prostatectomy.Prostate Cancer Prostatic Dis2024
37296271Artificial intelligence applications in prostate cancer.Prostate Cancer Prostatic Dis2024
35878714A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for Locally Advanced Prostate Cancer.Int J Radiat Oncol Biol Phys2023
37525535Use of the Decipher genomic classifier among men with prostate cancer in the United States.JNCI Cancer Spectr2023
37639648Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.J Clin Oncol2023
35790787Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer.Prostate Cancer Prostatic Dis2023
35688664The Impact of a Statewide Active Surveillance Initiative: A Roadmap for Increasing Active Surveillance Utilization Nationwide.Eur Urol2023
37461140Poly(adenosine diphosphate-ribose) polymerase inhibitor combinations in first-line metastatic castrate-resistant prostate cancer setting: a systematic review and meta-analysis.BJU Int2023
37060201A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.Cancer2023
37244961Future trends in incidence and long-term survival of metastatic cancer in the United States.Commun Med (Lond)2023
37236832Impact of Magnetic Resonance Imaging Targeting on Pathologic Upgrading and Downgrading at Prostatectomy: A Systematic Review and Meta-analysis.Eur Urol Oncol2023
37438199Re: Dose-escalated Radiotherapy Alone or in Combination with Short-term Androgen Deprivation for Intermediate-risk Prostate Cancer: Results of a Phase III Multi-institutional Trial.Eur Urol2023
37071764Implications of metastatic stage at presentation in docetaxel naïve metastatic castrate resistant prostate cancer.Prostate2023
37137444Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial.Int J Radiat Oncol Biol Phys2023
37003085Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.Eur J Cancer2023
37365062A Meta-analysis of the Efficacy and Safety of Stereotactic Arrhythmia Radioablation (STAR) in Patients with Refractory Ventricular Tachycardia.Clin Oncol (R Coll Radiol)2023
36966268Race-dependent association of clinical trial participation with improved outcomes for high-risk prostate cancer patients treated in the modern era.Prostate Cancer Prostatic Dis2023
37194261Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review.Expert Rev Anticancer Ther2023
36857621Reply to A. Abner et al.J Clin Oncol2023
36870853Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography.Eur Urol Oncol2023
36798177Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.Res Sq2023
36494221Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.Eur Urol2023
36894488Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial.Eur Urol2023
36630135Evaluation of Social Determinants of Health and Prostate Cancer Outcomes Among Black and White Patients: A Systematic Review and Meta-analysis.JAMA Netw Open2023
36596347Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials.Int J Radiat Oncol Biol Phys2023
36526390In Reply to Onal et al.Int J Radiat Oncol Biol Phys2023
36250542Characterization of Intercalated Cell Markers KIT and <i>LINC01187</i> in Chromophobe Renal Cell Carcinoma and Other Renal Neoplasms.Int J Surg Pathol2023
36179990External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis.Int J Radiat Oncol Biol Phys2023
36367998Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.J Clin Oncol2023
36269935Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials.J Clin Oncol2023
36097167Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer-exploratory analysis of LATITUDE study.Prostate Cancer Prostatic Dis2023
36264673Metastatic prostate cancer diagnosed by fine-needle aspiration: Contemporary cytopathologic and biomarker assessment with clinical correlates.Cancer Cytopathol2023
35918053Variations in Medical Necessity Determinations Across Commercial Insurance Carriers for Prostate Cancer Procedures.Int J Radiat Oncol Biol Phys2023
33303244Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer.Eur Urol2022
35383004Identification and Validation of the Prognostic Impact of Metastatic Prostate Cancer Phenotypes.Clin Genitourin Cancer2022
35737923Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601.J Clin Oncol2022
35840112Local Treatment of the Primary Tumor for Patients With Metastatic Cancer (PRIME-TX): A Meta-Analysis.Int J Radiat Oncol Biol Phys2022
35440417Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11].Eur Urol2022
35373440Development and validation of a life expectancy calculator for US patients with prostate cancer.BJU Int2022
35469702High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.Eur Urol2022
35465985Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis.Eur Urol2022
35721307Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men.NEJM Evid2022
35569476Bicalutamide Monotherapy With Radiation Therapy for Localized Prostate Cancer: A Non-Evidence-Based Alternative.Int J Radiat Oncol Biol Phys2022
35717045Lutetium-177 DOTATATE: A Practical Review.Pract Radiat Oncol2022
35717043Lutetium-177 Prostate-Specific Membrane Antigen Therapy: A Practical Review.Pract Radiat Oncol2022
35562350MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets.Nat Commun2022
35450732Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.Eur Urol2022
35657158Genomic biomarkers to guide precision radiotherapy in prostate cancer.Prostate2022
35513774Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer.BMC Cancer2022
35811293Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.Eur Urol Oncol2022
  • 1 - 50 of 398

Recommended Authors

Niluja Thiruthaneeswaran
The University of Sydney, Westmead Hospital
Career Start Year 2014
Number of shared co-authors 13
Pedro Isaacsson Velho
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Career Start Year 2013
Number of shared co-authors 33
Andrew Warner
Western University and London Regional Cancer Program
Career Start Year 2013
Number of shared co-authors 8
Darlene Veruttipong
Stanford University
Career Start Year 2012
Number of shared co-authors 13
Devin N Patel
university of california san diego School of Medicine
Career Start Year 2011
Number of shared co-authors 5
Izak Faiena
Columbia University Medical Center
Career Start Year 2010
Number of shared co-authors 8
Suneil Jain
Cancer Centre Belfast City Hospital, Queen's University Belfast
Career Start Year 2008
Number of shared co-authors 34
Jure Murgic
University Hospital Center Sestre Milosrdnice
Career Start Year 2008
Number of shared co-authors 21
John Thoms
Memorial University
Career Start Year 2008
Number of shared co-authors 13
Arun A Azad
Peter MacCallum Cancer Centre
Career Start Year 2007
Number of shared co-authors 20
Alastair D Lamb
University of Oxford
Career Start Year 2007
Number of shared co-authors 23
Adam Kinnaird
University of Alberta
Career Start Year 2007
Number of shared co-authors 11
Nicholas van As
The Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Career Start Year 2005
Number of shared co-authors 17
Jonathan L Wright
University of Washington Medical Center
Career Start Year 2005
Number of shared co-authors 39
Anne Y Warren
Cambridge University Hospitals National Health Service Foundation Trust
Career Start Year 2003
Number of shared co-authors 13
Scott T Tagawa
Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital
Career Start Year 2003
Number of shared co-authors 77
Andrew K Lee
Texas Center for Proton Therapy
Career Start Year 2001
Number of shared co-authors 5
Gregory R Pond
Juravinski Hospital and Cancer Centre, Escarpment Cancer Research Institute
Career Start Year 2001
Number of shared co-authors 22
Amit Bahl
University Hospitals Bristol and Weston NHS Foundation Trust
Career Start Year 2001
Number of shared co-authors 17
Vincent J Gnanapragasam
University of Cambridge
Career Start Year 1999
Number of shared co-authors 12
Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Career Start Year 1998
Number of shared co-authors 25
Niall M Corcoran
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1997
Number of shared co-authors 25
Gert De Meerleer
University Hospitals Leuven
Career Start Year 1997
Number of shared co-authors 42
Anthony M Joshua
The Kinghorn Cancer Centre, St. Vincent's Hospital Sydney
Career Start Year 1997
Number of shared co-authors 35
Glenn Bauman
Western University and London Regional Cancer Program
Career Start Year 1994
Number of shared co-authors 11
David I Quinn
USC Norris Comprehensive Cancer Center
Career Start Year 1993
Number of shared co-authors 41
Markus Graefen
University Hospital Frankfurt, Goethe University Frankfurt am Main
Career Start Year 1993
Number of shared co-authors 40
Choung-Soo Kim
Asan Medical Center, University of Ulsan College of Medicine
Career Start Year 1993
Number of shared co-authors 14
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 1990
Number of shared co-authors 78
Freddie C Hamdy
University of Oxford
Career Start Year 1987
Number of shared co-authors 37

Collaborators

Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 103
Robert T Dess
University of Michigan ann arbor
Co-authored papers 59
Amar U Kishan
University of California los angeles
Co-authored papers 55
Todd M Morgan
University of Michigan ann arbor
Co-authored papers 54
Paul L Nguyen
Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School
Co-authored papers 53
Rohit Mehra
Michigan Center for Translational Pathology.
Co-authored papers 49
William C Jackson
University of Michigan ann arbor
Co-authored papers 45
Brandon A Mahal
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine
Co-authored papers 41
Edward M Schaeffer
Northwestern University Feinberg School of Medicine
Co-authored papers 41
Elai Davicioni
Veracyte Inc.
Co-authored papers 40
Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers 33
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Co-authored papers 31
Howard M Sandler
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 31
Nicholas G Zaorsky
University Hospitals Seidman Cancer Centre, Cleveland Medical Centre
Co-authored papers 29
Robert Jeffrey Karnes
Mayo Clinic
Co-authored papers 28
Nicholas G Nickols
University of California, Veteran Affairs Greater Los Angeles Healthcare System
Co-authored papers 27
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 24
Michael L Steinberg
University of California los angeles
Co-authored papers 24
Ashley E Ross
Northwestern University
Co-authored papers 23
Robert B Den
Thomas Jefferson University Hospital
Co-authored papers 23
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Co-authored papers 21
Phuoc T Tran
University of Maryland School of Medicine
Co-authored papers 21
Thomas M Pisansky
Mayo Clinic
Co-authored papers 19
Jeffrey J Tosoian
Vanderbilt University Medical Center
Co-authored papers 18
Alejandro Berlin
University of Toronto, Princess Margaret Cancer Centre
Co-authored papers 17
Eric A Klein
Cleveland Clinic
Co-authored papers 17
Jeff M Michalski
Washington University School of Medicine
Co-authored papers 16
Simpa S Salami
University of Michigan Medical School ann arbor
Co-authored papers 16
Stephen J Freedland
Cedars-Sinai Medical Center
Co-authored papers 16
Mohammed Alshalalfa
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
Co-authored papers 14
Release 1.2